CANCER BIOLOGY & THERAPY 2016, VOL. 17, NO. 9, 911–914 http://dx.doi.org/10.1080/15384047.2016.1210738

BEDSIDE TO BENCH REPORT

Isolated splenic metastasis from a thymic carcinoma: A case report Dongmei Chena,b, Xiangying Mengb, Yaowei Zhaob, and Shikai Wua,b a Department of Radiation Oncology, Hospital of PLA, Clinical College, Anhui Medical University, Beijing, P.R. China; bDepartment of Radiation Oncology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, P.R. China

ABSTRACT

ARTICLE HISTORY

Thymic carcinomas are rare tumors that arise in the anterior mediastinum. Most of these malignancies develop local metastases limited in the thorax. Splenic metastases from thymic carcinomas are extremely rare. Here we report a case of isolated splenic metastasis from a 38-year-old female patient with Stage IV thymic carcinoma, who was treated with chemoradiotherapy. At twenty-2 months follow-up, the patient was found to have an isolated spleen metastasis, which was treated by Cyberknife with a reduced size of the metastasis, representing a partial response. Although splenic metastasis is a rare phenomenon, physicians need to be aware of the possibility of such metastases.

Received 4 April 2016 Revised 31 May 2016 Accepted 3 July 2016 KEYWORDS

Chemotherapy; oligometastasis; PET/CT; radiation; SBRT; spleen metastasis; thymic carcinoma

Abbreviations: CT, computed tomography; FDG-PET, fluorodeoxyglucose positron emission tomography; SUVmax, maximum standardized uptake value; SBRT, stereotactic body radiation therapy; OS, overall survival

Introduction Thymic carcinomas originate from thymic epithelial cells, which are significantly different from thymoma in biological characteristics and prognosis. It is mainly metastasized by regional intrusion and hematogenous spread. Extrathoracic metastases are seen in less than 7 percent of patients at presentation, most commonly to the kidney, extrathoracic lymph nodes, liver, brain, adrenals, thyroid, and bone.1 Rare but not exceptional is metastasis occurring on spleen.

Case presentation A 38-year-old female patient presented with the symptoms of chest tightness and dyspnea. The chest CT (CT) scan revealed a voluminous mass in the left anterior mediastinum that measured 8.9 cm £ 8.0 cm, with pericardial and pleural effusion. The fluorodeoxyglucose positron emission tomography (FDGPET)/CT confirmed involvement in left anterior mediastinum, hilar lymph nodes, pericardium, pulmonary artery and aorta. Distant metastasis was not detected at that time. Pericardiocentesis and drainage cytology analysis showed a small amount of atypical cells. The biopsy of thymic mass revealed a poorly differentiated squamous carcinoma with expression of cytokeratins 5/6, P63 and absence of neuroendocrine and adrenal markers such as CD56, synaptophysin and NapsinA (Fig. 1). The patient was diagnosed as thymic squamous carcinoma in Stage IVb according to Masaoka staging system and received 7 cycles of chemotherapy with gemcitabine, cisplatin and angiogenesis inhibitor endostar. Follow-up imaging showed that the size of primary thymic carcinoma was reduced by 26% after 6 cycles of treatment. The patients received concurrent chemoradiotherapy with taxane following the completion of the CONTACT Shikai Wu

[email protected]

© 2016 Taylor & Francis Group, LLC

chemotherapy. The radiation therapy was delivered by 6 MV external beams with a dose of 66 Gy in 33 fractions for the primary tumor. She achieved complete response after radiotherapy and was followed with routine physical exam, abdominal ultrasound and chest CT scan every 3 months afterwards. Abdominal CT scan revealed a moderate contrast enhanced lesion that measured 4.5 cm £ 3.5 cm in her spleen at 22-month follow up visit. This finding was confirmed by PET/CT, with the maximum standardized uptake value (SUVmax) of 30.67 (Fig. 2). Whereas the thymic mass was stable with an SUVmax of 1.8 (Fig. 3). No metastatic lesions were detected in the liver, adrenal gland and abdominal lymph nodes. Biopsy of spleen metastasis was not performed due to patient’s refusal. Patient also refused surgery resection for this splenic mass. She was then treated with stereotactic body radiation therapy (SBRT) on Cyberknife (30Gy in 5 fractions) as alternative treatment. Abdominal CT (Fig. 4) showed that the volume of spleen metastasis reduced to 2.6 cm £ 3.5 cm at one month follow up, which indicates a partial response.

Discussion Thymic carcinomas are rare and aggressive thymic epithelial tumors, accounting for only 0.06% of all thymic neoplasms.2 Thymic carcinomas are usually moderately differentiated squamous carcinomas, which account for 40.0%–77.5%.3-5 Some authors agreed that squamous carcinomas have more favorable prognosis than other histologic subtypes, such as lymphoepithelioma, sarcomatoid carcinoma and undifferentiated carcinoma.6 There are several systems to stage thymic carcinomas. Currently the WHO system is widely used and well correlates with Masaoka staging. About 65% thymic carcinomas, in WHO type C, had stage III or IV diseases with

Department of Radiation Oncology, Hospital of PLA, Beijing, P.R. China

912

D. CHEN ET AL.

Figure 1. (A) Hematoxylin-Eosin staining of the thymic mass showed tumor cells grew diffusely. Immunohistochemical analysis demonstrated the tumor cells were strongly positive for (B) P63, (C) cytokeratins 5/6, immunostaining revealed negative for (D) CD56, (E) synaptophysin and (F) NapsinA respectively.

Figure 2. Abdominal computed tomography (CT) scan revealed a moderate contrast enhanced lesion that measured 4.5 cm £ 3.5 cm in the spleen (A), which was confirmed by fluorodeoxyglucose positron emission tomography (PET/CT), with the SUVmax of 30.67 (B).

CANCER BIOLOGY & THERAPY

913

Figure 3. Chest CT and PET/CT showed the thymic mass was stable, which was not enhanced in chest contrast enhanced CT (A) and seen in PET/CT with a SUVmax of 1.8 (B).

Masaoka staging.7 The early stage thymic carcinomas occur locally and may require surgical resection with favorable prognosis. By contrast, stage III and IV thymic carcinomas appear to be more aggressive with distant metastases. The recommended therapy for invasive thymoma has been radical surgical resection. For the patients with inoperable or recurrent diseases, chemotherapy is the alternative treatment.8 If the tumor is not resectable after neoadjuvant chemotherapy, additional chemotherapy and/or radiotherapy can be used. Standard chemotherapy for thymic carcinomas remains undefined. Yusuke Okumaf and his colleagues believed that cisplatinbased chemotherapy might be superior to carboplatin-based chemotherapy for advanced thymic carcinomas, with the response rates of 53.6% and 32.8% respectively.9 Radiotherapy is necessary and important for this type of patients despite resection is complete or incomplete.10 The median survival time is 48 months in patients with thymic carcinomas11 and 5-year survival rates ranges from 28% to 60%.12,13 Splenic metastases present with an incidence of only 0.3%– 7.3% in autopsy reports.14 The most common primary sites of

splenic metastases originate from lung, breast, ovary, and colon. Rare metastatic sites reported are kidney, prostate, skin, endometrium.15 Most patients with splenic involvement usually present with multi-visceral disseminated diseases. Isolated splenic metastasis is exceedingly rare. There are some hypotheses that might explain this phenomenon. Anatomically, it is lack of afferent lymphatics and the acute angle of the splenic artery from the celiac artery, which may prevent large clumps of tumor cells from getting access to the spleen. Rhythmic contractions of the spleen force the blood flow from the sinusoids to the splenic veins, which, in case of constant blood flow, could prevent tumor fixation.16 In addition, the spleen, which includes amount of lymphocytes and macrophagocytes, serves the immune function to inhibit the induction and growth of tumor cells.17 Splenic metastasis primary from thymic carcinoma is quite uncommon. According to literature, only 2 cases have been reported so far.18,19 The patient discussed in the paper revealed a limited disease in advanced carcinoma. As the patient refused to perform surgical resection for this mass, we performed localized therapy with Cyberknife instead of chemotherapy for this isolated metastasis. Hellmanand and Weichselbaum20 proposed a theory that oligometastatic state was that for many cancers, a few metastases exist at first, before the malignant cells acquire widespread metastatic potential. Localized therapies including surgery and SBRT are radical treatment options to achieve control of metastatic sites. One recent study21 of SBRT for oligometastases reported that local control rates was 84.4%, the overall survival (OS) was 84.4% at 1 y and 63.2% at 2 y. A partial response was observed in our case with local Cyberknife therapy and patient is still followed by our group closely. In summary, although it is extremely rare, splenic metastasis should be taken into consideration in patients with thymic carcinomas. Radiotherapy is radical treatment option for isolated metastasis. Long-term follow-up is crucial to detect disease progression since recurrences are frequent.

Figure 4. Abdominal CT after radiotherapy: The patient was treated with Cyberknife for her spleen lesion. Abdominal CT showed that the spleen metastasis reduced to 2.6 cm £ 3.5 cm at one month follow up.

Disclosure of potential conflicts of interest No potential conflicts of interest were disclosed.

914

D. CHEN ET AL.

References 1. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987; 60:2727-43; PMID:3677008; http://dx.doi.org/10.1002/1097-0142(19871201) 60:113.0.CO;2-D 2. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125:434-6; PMID:12579125; http://dx.doi.org/10.1067/mtc.2003.133 3. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77:1860-9; PMID:15111216; http://dx.doi.org/10.1016/j. athoracsur.2003.10.001 4. Suster S, Rosai J. Thymic carcinoma: A clinicopathologic study 60 cases. Cancer 1991; 67:1025-32; PMID:1991250; http://dx.doi.org/10.1002/ 1097-0142(19910215)67:43.0.CO;2-F 5. Filosso PL, Guerrera F, Rendina AE, Bora G, Ruffini E, Novero D, Ruco L, Vitolo D, Anile M, Ibrahim M, et al. Outcome of surgically resected thymic carcinoma: a multicenter experience. Lung cancer 2014; 83:205-10; PMID:24370198; http://dx.doi.org/10.1016/j. lungcan.2013.11.015 6. Daisuke N, David K, Juan R. Thymic mucoepidermoid carcinomas: a clinicopathologic study of 10 cases and review of the literature. Am J Surg Pathol 2004; 28:1526-31; PMID:15489658 7. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004; 22:1501-9; PMID:15084623; http://dx.doi.org/10.1200/JCO.2004.10.113 8. Kelly RJ, Petrini I, Rajan A, Wang Y, Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011; 29:4820-7; PMID:22105817; http://dx.doi.org/10.1200/ JCO.2011.36.0487 9. Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2015; 141:323-31; PMID:25146529; http://dx.doi.org/10.1007/s00432-014-1800-6 10. Wang J, Zhang S. Advances on diagnosis and treatment of malignant thymic tumors. Chin J Lung cancer 2010; 13:985-91; PMID:20959073; http://dx.doi.org/10.3779/j.issn.1009-3419.2010.10.10

11. Lanting G, Changlu W, Wentao F, Jie Z, Changxing L, Shen F. Outcome of multimodality treatment for 188 cases of type B3 thymoma. J Thorac Oncol 2013; 8:1329-34; PMID:24457243; http://dx.doi.org/ 10.1097/JTO.0b013e31829ceb50 12. Yau-Lin T, Shan-Tair W, Ming-Ho W, Mu-Yen L, Wu-Wei L, FenFen C. Thymic carcinoma: involvement of great vessels indicates poor prognosis. Ann Thorac Surg 2003; 76:1041-5; PMID:14529981; http:// dx.doi.org/10.1016/S0003-4975(03)00831-2 13. Kazuya K, Yasumasa M. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76:878-84; PMID:12963221; http://dx.doi.org/10.1016/S0003-4975 (03)00555-1 14. Lam KY, Tang V. Metastatic tumors to the spleen: a 25-year clinicopathologic study. Arch Pathol Lab Med 2000; 124:526-30; PMID: 10747308; http://dx.doi.org/10.1043/0003-9985(2000)1242.0.CO;2 15. Gupta T, Nair N, Fuke P, Bedre G, Basu S, Shrivastava SK. Splenic metastases from cervical carcinoma: a case report. Int J Gynecol Cancer 2006; 16:911-4; PMID:16681784; http://dx.doi.org/10.1111/j.15251438.2006.00220.x 16. NisaldaMartins, SandraLamelas, Javier. Isolated splenic metastasis of colon cancer: a case report and literature review. Jcoloproctol 2012; 32:88-93; http://dx.doi.org/10.1590/S2237-93632012000100014 17. Capizzi PJ, Allen KB, Amerson JR, Skandalakis JE. Isolated splenic metastasis from rectal carcinoma. South Med J 1992; 85; PMID:1411716; http://dx.doi.org/ 10.1097/00007611-199210000-00017 18. Guillan RA, Zelman S, Smalley RL, Iglesias PA. Malignant thymoma associated with myasthenia gravis, and evidence of extrathoracic metastases. An analysis of published cases and report of a case. Cancer 1971; 27:823-30; PMID:5574073; http://dx.doi.org/10.1002/1097-0142 (197104)27:43.0.CO;2-X 19. Kao H, Lin W, Peng Y, Chen C. Unusual isolated splenic metastasis secondary to thymic carcinoma. Chin J Radiol 2005; 30:189-192 20. Rr HS, Weichselbaum. Oligometastases. J Clin Oncol 1995; 13:8-10; PMID:7799047 21. Bhattacharya IS, Woolf DK, Hughes RJ, Shah N, Harrison M, Ostler PJ, Hoskin PJ. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. Br J Radiol 2015; 88:20140712; PMID:25679321; http://dx.doi.org/ 10.1259/bjr.20140712

Isolated splenic metastasis from a thymic carcinoma: A case report.

Thymic carcinomas are rare tumors that arise in the anterior mediastinum. Most of these malignancies develop local metastases limited in the thorax. S...
862KB Sizes 2 Downloads 33 Views